Breaking News

GW Pharma Names Clinical Science VP

May 6, 2014

Sommerville to support U.S. regulatory activities for epilepsy programs

Kenneth Sommerville MD, has been appointed to the newly created position of vice president of clinical science at GW Pharmaceuticals. Dr. Sommerville will be based in the U.S. and will oversee clinical development, medical affairs, and regulatory activities related to the company's epilepsy programs, including Epidiolex, GW's product candidate for Dravet and Lennox-Gastaut syndromes. He will also support the late-stage completion of the investigational program for Sativex in cancer pain.
 
Dr. Sommerville, a board-certified neurologist, brings 23 years of pharmaceutical industry experience. Dr. Sommerville joins the company from Pfizer, where he served as vice president of clinical sciences and led a team in the development of abuse-deterrent opioids. He has also held senior roles at UCB/Schwarz Pharma where he led clinical and regulatory programs in epilepsy and other neurological product development initiatives.
 
"We are delighted to announce this important appointment and welcome Ken's extensive industry experience and therapeutic expertise in support of our rapidly evolving programs in the U.S.," said Justin Gover, GW's chief executive officer. "Ken will play a leading role in the clinical development of Epidiolex in the U.S. His expertise and depth of knowledge in product development and regulatory matters will serve GW well as we seek to advance Epidiolex through clinical trials and, if successful, obtain FDA approval as rapidly as possible."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016